Proact Q3’20 review: EBITA 2021 raised by 12% due to lowered SG&A

Research Note

2020-10-26

07:20

Redeye takes a neutral stance on Proact following a strong Q3, where solid cost control boosted EBITA. The turnaround seems almost complete, and we appreciated the acquisition of Cetus, supporting further profit growth. We increase our Base case.

FN

Fredrik Nilsson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.